New York City

Arrested Development"/> Up until October 2nd 2011, the idea that we might one day be watching new episodes of Arrested Development seemed about as likely as Tobias and Lindsay making sweet sweet love. Despite the cult that had grown around the show in the years since it was cancelled—and despite the casts' constant chatter about the "movie"—new Arrested Development seemed as likely as a new My Bloody Valentine record. Of course, we know how that turned out: we got a new MBV album, and starting at 3 a.m. EST/12 p.m. PST Sunday, new episodes of Arrested Development. [ more › ]

Documentary film director Alex Gibney's no stranger to controversial figureheads—he's profiled everyone from Eliot Spitzer to the Enron crew. In his latest film, We Steal Secrets: The Story of WikiLeaks, Gibney takes on Julian Assange, the embattled founder of the now-infamous classified information sharing site. We chatted with Gibney about Assange, whistleblowers, WikiLeaks and the dual dangers and necessity of information-sharing in the age of the Internet. [ more › ]

It's been a week since the horrific Metro-North collision that injured dozens of commuters, and the first federal lawsuit against the railroad has now been filed. A 65-year-old woman who says she was injured in the crash is suing Metro-North for negligence; her attorney says she is in critical condition and has suffered a brain injury. [ more › ]

It feels comforting to know that in a world in which so many things are changing for the better, some things will always remain the same: hot dog hookers will keep hot dog hooking, Chris Christie and Snooki will never be friends, and the club elite in the Hamptons will always find the douchiest ways imaginable to imbibe ridiculously expensive alcohol. Because everyone knows that the only thing cooler than a $25K bottle of champagne is a $25K bottle of champagne chilled during a 10,000-foot free-fall and served by a skydiver. [ more › ]

When the final part of the spire was lifted and installed on to the top of One World Trade Center, the Port Authority attached a camera to the bottom—remember this video, delivering 9 full minutes of vertigo that's still making our palms sweat? Anyway, around that time they ALSO took some other photos... FROM ABOVE, like this one. [ more › ]

@AmandaBynes : Don’t believe the reports about me being arrested. It’s all lies. I was sexually harassed by one of the cops the night before last which is who then arrested me. He lied and said I threw a bong out the window when I opened the window for fresh air. Hilarious. He slapped my vagina. Sexual harassment. Big deal. I then called the cops on him. He handcuffed me, which I resisted, quite unlike any of the reports stated. Then I was sent to a mental hospital. Offensive. I kept asking for my lawyer but they wouldn’t let me. The cops were creepy. The cop sexually harassed me, they found no pot on me or bong outside my window. That’s why the judge let me go. Don’t believe any reports. Well. Here we go folks. This is it. Stage 5 Crazy. An unchartered meltdown. I thought it would take another few months to take this breakdown to the next level and it actually took about 36 hours. Claiming police officers slapped your pussy is some next level shit. She continues to impress, continues to out do herself. She’s absolutely relentless with the crazy. And yes, if you’re wondering, I am absolutely fantasizing about slapping Bynes’ pussy

The filmh focuses on the lives of A Tribe Called Quest's members some 25 years after they first thrillingly appeared on the New York City underground rap radar, wowing audiences with their combination of inventive sampling, conscious lyricism and Afrocentric aesthetics.Promoted as the first-ever documentary to focus on a hip-hop group, the film is very much an insider's look at Tribe's surprisingly tense behind-the-scenes, in-group dynamics. It's an intense watch as members Q-Tip, Phife Dawg, Ali Shaheed Muhammed and Jarobi White openly discuss the sentiments of jealousy and burden that have fueled the band's on-again-off-again status since the late '90s.But it's not just the group's perspective that is shared: Throughout the documentary, Rapaport intersperses his footage of Tribe's performances, rehearsals and arguments with commentary from other influential hip-hop icons such as Questlove, The Beastie Boys, MC Lyte, Pharrell Williams and others, all of whom explain, defend and sometimes outright drool about Tribe's place atop the hip-hop world. It's not all glittery, though; one particularly enlightening scene finds Tribe's contemporaries in De La Soul openly hoping for the group's demise so that they won't be forced to watch their in-fighting any longer. Indeed: Beats, Rhymes & Life is an honest, insightful look into the history, present and possible future of one of hip-hop's greatest group of provocateurs. TRIBE CALLED QUEST BEATS RHYMES AND LIFE

“The Angels picked Harvey in the third round in 2007 knowing it would take first-round money to sign him out of high school, but when owner Arte Moreno authorized an offer of only $1 million — half of what Harvey wanted — the right-hander went to the University of North Carolina. Harvey signed for $2.6 million with the Mets in 2010 and, armed with a 97-mph fastball and devastating curve, has emerged as a Cy Young Award candidate…” - Mets’ Matt Harvey is one who got away - Los Angeles Times

A new book collecting the Madonna portraits show by Richard Corman in New York City in the early 80's will be published by Damiani on November 30, 2013. Madonna NYC 83 celebrates a moment in early...

UnitedHealth Group Incorporated (NYSE:UNH): Current price $62.04 UnitedHealthcare Community Plan has enlarged its New York State government-sponsored health insurance programs to include 13 more counties in the Hudson Valley, and the Capital and Central New York regions. UnitedHealthcare’s New York State government-sponsored health insurance programs were already available in New York City, on Long Island, and in Central New York. The Plan offers products for individuals and families who might qualify for Medicaid, Family Health Plus, Child Health Plus or New York Medicaid Advantage, or dual-eligible plans. These plans offer comprehensive health coverage that include hospitalization, prevention, primary care, prescriptions and other services, typically with little or no cost. NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW! Don’t Miss: Will Consumers Be Hurt By Obamacare? Johnson & Johnson (NYSE:JNJ): Current price $86.69 The company recently won FDA approval for the expansion of Simponi’s label, as the agency awarded Simponi approval for the treatment of adults suffering from moderately to severely active ulcerative colitis in case of corticosteroid dependence, or when the patients have not responded sufficiently to or are intolerant of oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine. The label expansion makes Simponi the first and sole subcutaneously administered anti-tumor necrosis factor therapy to obtain approval for the induction and maintenance of clinical response and improvement of endoscopic appearance of the mucosa during induction. NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW! Don’t Miss: Are These Companies Rigging Oil Prices? Merck & Co. (NYSE:MRK): Current price $47.11 On Wednesday, Merck’s experimental insomnia drug moved one step nearer FDA approval, after a panel of medical experts pronounced it effective and safe at lower doses. The advisory panel assisted the FDA in its decision whether or not to clear the drug, suvorexant, which would represent the first in a new class of sedatives that block chemicals in the brain called orexins that help keep persons awake. The drugs were created to help people fall asleep and stay asleep. On Monday, the FDA’s internal reviewers released a report expressing some fears regarding suvorexant’s potential to lead to next-day sleepiness and impaired driving, requesting the committee to consider whether patients should be started at a lower dose than that recommended by Merck. Merck has ceased development of preladenant, which is an experimental drug for Parkinson’s disease, after initial data from three late-stage trials was  disappointing. The company said that the decision to discontinue the studies was not based on any safety findings. Vice President, Clinical Research, Neuroscience and Ophthalmology at Merck Research Laboratories David Michelson said in a statement: “Parkinson’s disease is very complex, making it difficult to treat patients and develop novel therapeutic approaches. We are committed to neuroscience research and will be conducting further analyses of the data to inform the scientific community’s efforts in finding new approaches to treat this debilitating disease.” Merck announced that results of the studies will be presented at an upcoming scientific meeting and also submitted for publication in a medical journal. NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW! Pfizer (NYSE:PFE): Current price $29.03 Pfizer has recently suffered a pipeline setback with its discontinuing a late-stage evaluation being conducted with its oncology candidate, inotuzumab ozogamicin. The randomized, open-label, two-arm phase III study was being conduct